Abbott

Libertyville, United States Founded: 1888 • Age: 138 yrs Listed Fortune MNC 500 · #52
Developer of medical devices, generic pharmaceuticals, and nutrition products
Request Access
Report Incorrect Data
Page last updated

About Abbott

Abbott is a publicly listed company based in Libertyville (United States) founded in 1888. The company has 3,710 employees. Abbott has completed 29 acquisitions, including Alere, Bigfoot Biomedical and CFR Pharmaceuticals. Its chief executive, as recorded, is Robert B Ford. Its website abbott.com draws about 917 thousand monthly visits. Its Indian entity Abbott India Limited reported revenue of ₹7,249 Cr. Abbott offers products and services including FreeStyle Libre, BinaxNOW, and HeartMates Program. Its focus areas include Diversified Pharmaceuticals and Drugs.

Company details

Developer of medical devices, generic pharmaceuticals, and nutrition products. Its products are used by hospitals, laboratories, blood banks, and physicians. It is used to diagnose monitor diseases such as HIV, hepatitis, cancer, heart failure, and metabolic disorders. In 2022, the company recorded annual revenues of 43.65B and a net profit of 6.93B

Abbott is ranked #52 on the Fortune MNC 500 India (2026).

Recognitions & Rankings of Abbott

Fortune MNC 500 India 2026 edition
Rank#52
Total income
₹16,811 Cr
Profit
₹2,555 Cr
Last year #54
  • Headquarters Libertyville, United States
  • Employees 3,710
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website abbott.com
  • Social LinkedIn X Facebook Instagram YouTube
  • Legal Name Abbott Laboratories
Operational Areas
Healthcare → Pharmaceuticals & Distribution
Key Metrics
  • Market Cap
    ₹56,695 Cr

    ABBOTINDIA · NSE

  • Share Price
    ₹26,680.00

    -0.02% today

  • Revenue
    ₹6,960 Cr

    FY 2025-26 · +8.0% YoY

  • EBITDA
    ₹1,892 Cr

    Margin 27.2%

  • Net Profit
    ₹1,547 Cr

    FY 2025-26 · +9.3% YoY

  • P/E (TTM)
    56.6x

    P/B 17.5x

  • ROE
    34.5%

    ROCE 43.8%

  • Debt / Equity
    0.04

    Interest cover 1.4x

  • Latest Funding Round
    $11.29K (USD), Grant

    Nov 2021

  • Investors
    European Union
  • Employee Count
    3,710
  • Investments & Acquisitions
    Alere

    & 28 more

Products & Services of Abbott

Abbott offers a comprehensive portfolio of products and services, including FreeStyle Libre, BinaxNOW, and HeartMates Program.

FreeStyle Libre
Diabetes Care

Continuous glucose monitoring system for diabetes management.

BinaxNOW
Diagnostics

Rapid antigen test for detecting COVID-19 infections.

HeartMates Program
Heart Health

Support network for heart health recovery and awareness.

Apps and channels of Abbott

its YouTube channel Abbott has 581 subscribers and 30 videos.

Abbott
YouTube 581 subscribers 30 videos Autos & Vehicles
Open channel

Videos from Abbott

The most watched videos on Abbott's YouTube channel, Abbott (581 subscribers). Click a video to play it here.

Abbott x Real Madrid | Bottle Challenge
9.8K views
The We Give Blood Drive
8K views
Why We Run
4K views
CES 2025: Tracking Your Body’s Signals for Better Health, presented by Abbott
2.6K views

More on Abbott.

Funding Insights of Abbott

  • Total Rounds 21
  • Last Round Grant — $11,285
  • First Round $191,850

    (Apr 2015)

  • Investors Count 1

Latest 10 of 21 funding rounds of Abbott with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Nov 2021$11,285Grant––
European Union
Nov 2021$48,205Grant––
European Union
Oct 2021$34,646Grant––
European Union
May 2021$20,326Grant––
European Union
Mar 2021$47,339Grant––
European Union
Feb 2021$12.59MGrant––
European Union
Dec 2020$20,353Grant––
European Union
Jan 2020$44,017Grant––
European Union
Oct 2019$44,362Grant––
European Union
Dec 2018$18,329Grant––
European Union
Valuation history

1 investors in total: 1 institutional.

Investors in Abbott

Abbott has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include European Union.

All
Institutional
InvestorDescriptionFounded YearDomainLocation
European Union
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
1958europa.euBrussels, Belgium
Premium access

Investor details for Abbott

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Abbott India Limited (Abbott)

Abbott India Limited is the primary company behind Abbott. The boards of the 4 registered companies of Abbott currently have 22 directors; the longest-serving is Munir Shaikh, appointed in 2001. 84 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Munir Shaikh
DIN 00096273
Director02 Mar 200125 yrs 8 moAbbott India Limited
Venu Gopal Bang
DIN 03212996
Director30 Aug 201016 yrs 2 moSt. Jude Medical India Private Limited
Kaiyomarz Minoo Marfatia
DIN 03449627
Director01 Mar 201115 yrs 8 moAbbott India Limited
Sanjeev Johar
DIN 00479398
Director04 Oct 201214 yrs 1 moAbbott Diagnostics Medical Private Limited
Scott Michael Leinenweber
DIN 07265081
Director19 Aug 201511 yrs 2 moAbbott Healthcare Private Limited
Tushar Sharma
DIN 07775184
Director04 Aug 20179 yrs 3 moSt. Jude Medical India Private Limited
Ajay Singh Chauhan
DIN 08099794
Director04 Apr 20188 yrs 7 moSt. Jude Medical India Private Limited
Sudarshan Kailash Chandra Jain
DIN 00927487
Director01 Apr 20197 yrs 7 moAbbott India Limited
Shalini Kalsi Kamath
DIN 06993314
Director29 Oct 20197 yrsAbbott India Limited
Bradley Jay Slater
DIN 09807746
Director12 Dec 20223 yrs 10 moSt. Jude Medical India Private Limited
Ramanathan
DIN 10561088
Director01 Apr 20242 yrs 7 moAbbott Healthcare Private Limited
Alison Elizabeth Davies
DIN 10658884
Director13 Jun 20242 yrs 4 moAbbott India Limited
Kunal Chowdhury
DIN 10937790
Additional Director21 Feb 20251 yr 8 moAbbott Healthcare Private Limited
Maithilee Kaizad Mistry
DIN 02152619
CFO06 May 20251 yr 6 moAbbott India Limited
Kartik Rajendran
DIN 09527717
Managing Director14 Jun 20251 yr 4 moAbbott India Limited
Jagriti Kumar
DIN 07253311
Director25 Jul 20251 yr 3 moAbbott Diagnostics Medical Private Limited
Anirban Basu
DIN 11232068
Additional Director08 Aug 20251 yr 3 moAbbott Healthcare Private Limited
Darshan Pravin Gada
DIN 08174581
Director18 Aug 20251 yr 2 moAbbott India Limited
Rakesh Kumar Rajan
DIN 10909304
Director05 Dec 202511 moAbbott Diagnostics Medical Private Limited
Vivek Mohan
DIN 00075006
Director01 Jan 202610 moAbbott India Limited
James Russell Wenner
DIN 11650998
Director23 Apr 20266 moAbbott India Limited
Neeraj Jain
DIN 00348591
Director25 Apr 20266 moAbbott India Limited

People of Abbott

1329 people are tracked at Abbott (536 in leadership, 13 in board & advisors, 780 in team); the tracked headcount is 3,710.

NameRoleGroup
Robert B Ford
CEOLeadership
Robert Ford
CEOLeadership
Esther Chagoya
Director Strategic Initiatives And CommunicationsLeadership
Juan Manuel Fonseca Saravia
General ManagerLeadership
Charles Craig
Director Cybersecurity ServicesLeadership
Trevor Burlison
Area Vice PresidentLeadership
Diana Luo
Divisional Vice President, Commercial Legal, Structural Heart And Heart FailureLeadership
Eric Ryan
Director, Adult Global MarketingLeadership
Hoai Trinh
Regional HR DirectorLeadership
Lauren White
Director Of CybersecurityLeadership
Christian Moormann
Head of Product DevelopmentLeadership
Meghan Griffin
Global Clinical Program DirectorLeadership
Alexa Bisinger
Area Medical Director - AmericasLeadership
Vahe Ayvazian
Divisional Vice President Global DiagnosticsLeadership
Karen Rodriguez
Division Vice President Operations, Rapid DiagnosticsLeadership
Ding
Chief Cybersecurity ArchitectLeadership
Vildan Kehr
Divisional Vice President, Human Resources, Rapid And Molecular DiagnosticsLeadership
Ramon Neira
Division VP and Controller, Emerging Markets, Infectious Diseases, Rapid DiagnosticsLeadership
Darshan Gada
Regional Finance Director - Abbott IndiaLeadership
Dr. Ursula Christian
R&d Divisional Vice President Product Development, HematologyLeadership

1309 more people are available in the full profile.

Premium access

Complete people profiles for Abbott

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Abbott

Abbott is a publicly listed company on the NSE with ticker symbol ABBOTINDIA in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date08 Jan 2010
  • Listed onNSE: ABBOTINDIA
  • Listed entityAbbott India Limited
  • Exchange sectorHealth technology
  • ISINUS0028241000
  • Share price$102.61 (+0.78% on the day) · 2026-10-13
  • Market capitalisation$177.55B
  • Price to earnings33.2
  • EPS (diluted, trailing year)$3.09
  • Dividend yield2.42%
  • Volume (last session)9,864,564

Financials of Abbott

Exchange-reported figures of Abbott India Limited, the listed company behind Abbott (NSE: ABBOTINDIA).

Financial Highlights

FY 2025-26 · Standalone
Revenue
₹6,960 Cr
+8.0% YoY
EBITDA
₹1,892 Cr
+11.7% YoY
Profit After Tax
₹1,547 Cr
+9.3% YoY
Net Worth
₹4,774 Cr
+12.8% YoY
Total Assets
₹5,064 Cr
+11.3% YoY
Total Debt
₹172 Cr
-12.5% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue6,9606,4465,8755,3794,9194,3104,093
Revenue growth+8.0%+9.7%+9.2%+9.4%+14.1%+5.3%-
EBITDA1,8921,6951,4531,2061,088921756
EBITDA margin+27.2%+26.3%+24.7%+22.4%+22.1%+21.4%+18.5%
Profit before tax2,0791,8871,6181,2741,080926803
Net profit1,5471,4151,201950799691593
Net profit margin+22.2%+22.0%+20.4%+17.7%+16.2%+16.0%+14.5%
EPS (₹)730.36665.62565.28446.78375.86325.03279.03
Balance sheet
Total assets5,0644,5493,8973,3953,0642,8442,691
Net worth4,7744,2333,6993,1892,8202,6022,432
Total debt17219783.23113152153175
Cash & bank2,2551,6262,1341,9372,7492,4092,197
Net working capital2,3323,3951,9501,8652,6932,4912,349
Cash flow
Cash from operations1,3191,0121,213893948727626
Cash from investing(371)182(416)(148)(396)(71.82)(401)
Cash from financing(1,066)(925)(745)(639)(637)(582)(217)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue1,9511,8141,7101,7241,7571,7381,6051,614
Revenue growth (YoY)+11.0%+4.3%+6.5%+6.8%+7.6%+11.6%--
Other income68.0675.3775.5969.7669.9572.8476.0271.75
Total expenses1,3831,2911,2291,2611,2551,2931,1761,178
EBITDA568522481463502446429436
EBITDA margin+29.1%+28.8%+28.1%+26.9%+28.6%+25.6%+26.7%+27.0%
Depreciation19.4919.7519.0718.7718.6419.4817.9317.99
Interest5.955.916.145.487.555.823.922.26
Profit before tax610572531509546493483488
Tax157144136133131127116127

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 10 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue1,9511,8141,7101,7241,7571,7381,6051,614
Revenue growth (YoY)+11.0%+4.3%+6.5%+6.8%+7.6%+11.6%--
Other income68.0675.3775.5969.7669.9572.8476.0271.75
Total expenses1,3831,2911,2291,2611,2551,2931,1761,178
EBITDA568522481463502446429436
EBITDA margin+29.1%+28.8%+28.1%+26.9%+28.6%+25.6%+26.7%+27.0%
Depreciation19.4919.7519.0718.7718.6419.4817.9317.99
Interest5.955.916.145.487.555.823.922.26
Profit before tax610572531509546493483488
Tax157144136133131127116127
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue6,9606,4465,8755,3794,9194,3104,093
Revenue growth+8.0%+9.7%+9.2%+9.4%+14.1%+5.3%-
Other income28827624815477.2180.90114
Total expenses5,0684,7514,4224,1733,8323,3893,337
Employee cost669588577564579493476
EBITDA1,8921,6951,4531,2061,088921756
EBITDA margin+27.2%+26.3%+24.7%+22.4%+22.1%+21.4%+18.5%
Depreciation75.9671.8071.1769.9766.1058.1359.61
Interest24.9911.4312.4515.9919.1018.288.53
Profit before tax2,0791,8871,6181,2741,080926803
Tax527473417324281235210
Net profit1,5471,4151,201950799691593
Net profit margin+22.2%+22.0%+20.4%+17.7%+16.2%+16.0%+14.5%
EPS (₹)730.36665.62565.28446.78375.86325.03279.03
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital21.2521.2521.2521.2521.2521.2521.25
Reserves & surplus4,7534,2123,6783,1672,7992,5812,410
Shareholders' funds (net worth)4,7744,2333,6993,1892,8202,6022,432
Secured loans0.000.000.000.000.000.000.00
Unsecured loans17219783.23113152153175
Total debt17219783.23113152153175
Total liabilities5,0644,5493,8973,3953,0642,8442,691
Assets
Gross block567553424367382341345
Net block331336225237271251270
Capital work in progress5.5118.0810.113.660.660.661.64
Investments0.000.000.000.000.000.000.00
Inventories947882620649688718527
Sundry debtors362380319317288250318
Cash & bank balances2,2551,6262,1341,9372,7492,4092,197
Loans & advances2071,875173122128111162
Total current assets3,7714,7633,2463,0253,8533,4873,205
Total current liabilities1,4381,3681,2961,1601,160996855
Net working capital2,3323,3951,9501,8652,6932,4912,349
Total assets5,0644,5493,8973,3953,0642,8442,691
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash561292240133218145137
Net cash from operating activities1,3191,0121,213893948727626
Net cash from investing activities(371)182(416)(148)(396)(71.82)(401)
Net cash from financing activities(1,066)(925)(745)(639)(637)(582)(217)
Net change in cash(118)26952.07107(85.56)73.138.13
Closing cash2,2551,6262,1341,9372,7492,4092,197
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+8.0%+9.7%+9.2%+9.4%+14.1%+5.3%-
EBITDA growth+11.7%+16.6%+20.5%+10.8%+18.0%+21.8%-
PBT growth+10.2%+16.6%+27.0%+18.0%+16.6%+15.4%+14.9%
Net income growth+9.3%+17.8%+26.5%+18.9%+15.6%+16.4%-
Revenue CAGR (3Y)+9.0%+9.4%+10.9%+9.5%+10.2%+9.3%+12.1%
EBITDA CAGR (3Y)+16.2%+15.9%+16.4%+16.8%+21.6%+20.7%+23.9%
Profitability & leverage
Net income margin+22.3%+21.9%+20.5%+17.7%+16.2%+16.0%+14.5%
Return on capital employed+43.8%+45.0%+44.7%+39.9%+37.2%+34.1%+34.0%
Return on net worth+34.5%+35.7%+34.9%+31.6%+29.5%+27.4%+26.7%
Debt / equity0.040.040.030.040.060.070.04
Long-term debt / equity0.030.020.020.030.040.050.03
Interest cover1.380.700.901.411.872.121.22
Efficiency & per share
Fixed asset turnover12.4313.1914.8514.3713.6212.5816.08
Inventory turnover7.618.599.268.057.006.937.22
Debtors turnover18.7618.4318.4717.7818.2715.1713.78
EPS (₹)730.36665.62565.28446.78375.86325.03279.03
Dividend per share (₹)656.00475.00410.00325.00275.00275.00250.00
Book value per share (₹)2,246.681,992.071,740.651,500.491,326.961,224.551,144.33

Investments & Acquisitions by Abbott

Abbott has strategically engaged in corporate development activities, having acquired 29 companies. Notable acquisitions include Alere, Bigfoot Biomedical and CFR Pharmaceuticals.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Exact Sciences
Non-invasive molecular diagnostic tests for cancer detection are provided.
exactsciences.comMadison, United States1995Mar 2026••••
LARALAB
Digital decision support tools are provided to healthcare providers.
laralab.comMunich, Germany2017Oct 2025••••
Bigfoot Biomedical
Developer of a closed-loop automated insulin delivery system
bigfootbiomedical.comMilpitas, United States2014Sep 2023••••
Cardiovascular Systems
Devices for treating peripheral and coronary vascular disease are developed.
csi360.comSaint Paul, United States1989Feb 2023$890M
JETi
Manufacturer of vascular care devices
jeti.tvIrvine, United States2018Sep 2021••••
Cephea Valve Technologies
Catheter-delivered mitral valves are developed with non-stent anchoring technology.
cephea.comSanta Clara, United States2013Jan 2019••••
St. Jude Medical
Medical devices for cardiac and neuromodulation therapies are manufactured globally.
sjm.comSaint Paul, United States1976Apr 2016$25B
Kalila Medical
Steerable introducer sheaths are developed for electrophysiology procedures.
kalilamedical.comCampbell, United States2010Feb 2016••••
Alere
Developer of small rapid diagnostic devices for infectious diseases
alere.comWaltham, United States1991Feb 2016$5.3B
Tendyne Holdings
Transcatheter mitral valve replacement prosthesis for regurgitation is developed.
tendyne.comRockville, United States2010Jul 2015$225M
Premium access

Complete acquisition details for Abbott

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Abbott

14 dated milestones of Abbott across 138 years, from founding to its latest funding, stage changes and deals.

  1. Founded Abbott is founded.
  2. IPO Lists on the stock exchange (IPO).
  3. Funding First funding round of $192K.
  4. Acquisition Acquires Tendyne Holdings.
  5. Acquisition Acquires Alere.
  6. Acquisition Acquires Kalila Medical.
  7. Acquisition Acquires St. Jude Medical.
  8. Acquisition Acquires Cephea Valve Technologies.
  9. Acquisition Acquires JETi.
  10. Funding Latest funding round, Grant, of $11K.
  11. Acquisition Acquires Cardiovascular Systems.
  12. Acquisition Acquires Bigfoot Biomedical.
  13. Acquisition Acquires LARALAB.
  14. Acquisition Acquires Exact Sciences.

Web traffic of Abbott

The website of Abbott (abbott.com) receives about 917.2K visits a month and ranks #65,577 among all websites worldwide, #1,810 in Health.

  • Monthly visits
    917.2K

    ▲ 12.5% vs previous month

  • Unique visitors
    343.9K

    per month

  • Global rank
    #65,577

    among all websites

  • Category rank
    #1,810

    Health · Health

Similar websites

Websites whose visitors overlap most with Abbott. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
abbottnutrition.com
abbottnutrition.com
100%
#333,869–
Boehringer Ingelheim
boehringer-ingelheim.com
99%
1.6M#39,825View details
abbott.sharepoint.com
abbott.sharepoint.com
99%
–
Lilly
lilly.com
99%
4.9M#13,252View details
GSK
gsk.com
97%
1.3M#56,834View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 40 similar websites and full traffic analytics for Abbott

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 40 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Pharmaceuticals & Distribution

3 companies that operate in the same segment as Abbott (Pharmaceuticals & Distribution) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Roivant Sciences
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
2014New York, New York, United StatesUSD 1.3 BUSD 8.26 M750
Amgen
Developer of pharmaceutical products for treating multiple diseases
1980Thousand Oaks, California, United StatesUSD 33.23 B28,000
AbbVie
Biopharmaceutical research and drug development are conducted globally by AbbVie.
2012Chicago, Illinois, United StatesUSD 5.33 B55,000
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Abbott

Abbott India: JPMorgan on Abbott India maintains Neutral, Target Price Rs 30800; Q2 revenue, EBITDA and PAT grew 11%, 13% and 9% YoY, respectively, with PAT missing estimates due to lower other income and higher finance costs. The company's own portfolio, excluding Novo, grew 17% YoY, supporting a 50bps improvement in EBITDA margin to 29.1%. JPMorgan raised FY28–29 revenue estimates by 4–5%, while noting limited traction in the Semaglutide injectable franchise amid rising competition.
Exchange Update • 4 days ago
ABBOTINDIA: Q2 EBITDA 5.68B RUPEES VS 5.02B (YOY); Q2 EBITDA MARGIN 29.11% VS 28.58% (YOY)
Exchange Update • 5 days ago
ABBOTINDIA: Q2 REVENUE 19.51B RUPEES VS 17.57B (YOY)
Exchange Update • 5 days ago
ABBOTINDIA: Q2 STANDALONE NET PROFIT 4.53B RUPEES VS 4.15B (YOY)
Exchange Update • 5 days ago
Abbott and Sesame Workshop India Partner to Teach Healthy Habits to Children
The Tribune • 29 days ago
FDA clears Abbott’s CardioMEMS HF system updates
Hospital Management • 1 month ago
Abbott Launches SimpleScreen Blood Test for Colorectal Cancer in U.S.
Medical Product Outsourcing • 1 month ago
Abbott Partners with Berry Street to Integrate Nutrition Coaching with Lingo CGM
Drug Delivery Business • 1 month ago
Tennessee secures $2.35 million baby formula settlement
Nashville Post • 1 month ago
Mid-cap stocks: For investors who know and accept that bears can roam the street longer: 5 mid-cap stocks with upside potential of up to 29% - The Economic Times
Economic Times • 1 month ago
Premium access

Complete news archive for Abbott

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Abbott

Abbott was founded in 1888 and raised its 1st funding round 127 years after it was founded.

Abbott is headquartered in Libertyville, United States. It is registered at Libertyville, Illinois, United States.

Robert B Ford is the CEO of Abbott, as recorded in our data.

Abbott has 3,710 employees.

The primary company behind Abbott, Abbott India Limited, reported revenue of ₹7,249 Cr for FY 2026, up 8% year on year.

Developer of medical devices, generic pharmaceuticals, and nutrition products. Its products are used by hospitals, laboratories, blood banks, and physicians. It is used to diagnose monitor diseases such as HIV, hepatitis, cancer, heart failure, and metabolic disorders. In 2022, the company recorded annual revenues of 43.65B and a net profit of 6.93B.

Abbott offers FreeStyle Libre, BinaxNOW, and HeartMates Program.

Yes, Abbott is publicly traded on NSE under the ticker symbol ABBOTINDIA.

Abbott has made 29 acquisitions, including Alere, Bigfoot Biomedical, and CFR Pharmaceuticals.

Abbott has 1 investor. Key investors include European Union.

Abbott is associated with 4 legal entities: Abbott India Limited, Abbott Diagnostics Medical Private Limited, Abbott Healthcare Private Limited and others.

The legal entities of Abbott currently have 27 directors, including Sanjeev Johar, Jagriti Kumar, Rakesh Kumar Rajan and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available